Stocks · Torrent Pharma vs Divi's Labs
Torrent Pharmaceuticals vs Divi's Labs: branded pharma or specialty manufacturing?
Branded formulations franchise versus specialty API and custom manufacturing excellence. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Torrent Pharmaceuticals is the branded formulations story where therapy execution and domestic plus international product mix drive performance, while Divi's Laboratories is the specialty ingredients and custom synthesis compounder where process excellence and long client relationships are the core moat. As of 2026-06-16, the systematic read scores Torrent Pharmaceuticals Limited 94 and Divi's Laboratories Limited 89 on the BazaarBaazi Crack Score, an Edge Score of 55 out of 100 to Torrent Pharmaceuticals Limited.
BazaarBaaziSource & method
The matchup, at a glanceTORNTPHARM 94 · DIVISLAB 89
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Torrent Pharmaceuticals Limited
Crack Score
94 / 100Bullish
Structural edges
- Branded formulations identity gives it a consumer-facing pharma story with pricing power in the chronic therapy segments it leads.
- Therapy-franchise building and domestic prescription leadership create durable market positions that compound over time.
- A developed-market generics pipeline adds an optionality layer beyond the domestic branded book.
The case for
Divi's Laboratories Limited
Crack Score
89 / 100Bullish
Structural edges
- Process chemistry depth and a regulatory compliance track record support a premium quality perception that attracts global innovator mandates.
- Custom synthesis from innovator pharma companies is a high-value, long-duration relationship that offers better margin visibility.
- A focused business model in specialty manufacturing makes the investment thesis simpler to track than a multi-geography branded pharma story.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Torrent Pharmaceuticals Limited | Divi's Laboratories Limited | |
|---|---|---|
| Return on equity | n/a | 15.3% |
| Net profit margin | n/a | 24.3% |
| EPS growth (YoY) | n/a | +17.4% |
| Debt to equity | n/a | 0.00 |
Stored from each company's filed results, as of 2026-06-16 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Torrent Pharmaceuticals Limited | Divi's Laboratories Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharma APIs and CDMO |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~1.5 lakh cr | ~1.8 lakh cr |
| Crack Score | 94 / 100 | 89 / 100 |
| Systematic stance | Bullish | Bullish |
| What they do | A pharma company anchored in branded formulations across therapeutic areas, with a domestic prescription franchise and a growing international generics business. | A specialty API and custom synthesis company that manufactures active pharmaceutical ingredients and intermediates for global pharma clients. |
| The moat | Brand leadership in specific therapeutic franchises in the domestic market, a developed-market generics pipeline and a distribution reach built over decades. | Process chemistry depth, regulatory compliance consistency and long-standing client relationships with global innovator and generic drug companies. |
| Key driver 2026 to 2030 | Domestic branded prescription growth, developed-market generics launches, new therapeutic franchise additions and profitability from the chronic and acute therapy mix. | Custom synthesis wins from innovator pharma companies, nutraceuticals revenue, API demand cycles and the pace of new client and molecule additions. |
| Main risk | Branded pharma competition, market share loss in key therapeutic areas and execution in the developed-market generics filing pipeline. | Client concentration risk, API pricing cycles, regulatory inspection outcomes and volume dependence on a relatively small number of high-value molecules. |
| Best suited to | The investor who wants a branded pharma franchise with a visible prescription-market story and a developed-market generics pipeline as optionality. | The investor who wants a high-quality specialty manufacturing compounder where process discipline and client stickiness are the long-term earnings drivers. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on TORNTPHARM and DIVISLAB.
FAQ4 reader questions · AEO-eligible
The Torrent Pharma vs Divi's Labs call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
Is Torrent Pharma or Divi's Labs a better stock to buy?
Torrent Pharmaceuticals is the branded formulations story with domestic therapy leadership and generics optionality, while Divi's Labs is the specialty manufacturing compounder with process discipline and innovator client relationships. Pick branded pharma versus specialty manufacturing, and use the fundamentals calculator to compare each company's current P/E and return on capital from the latest results.
What is Divi's Labs known for?
Divi's Laboratories is best known for its expertise in manufacturing active pharmaceutical ingredients and custom synthesis, particularly for global innovator pharma companies. Its Vizag and Kakinada plants have built a reputation for process quality and regulatory compliance over many years.
How does Torrent Pharma compare with larger domestic pharma players?
Torrent Pharmaceuticals is a mid-size branded pharma company with a focused chronic therapy portfolio in the domestic market and a growing generics business internationally. It is smaller than the top-tier names like Sun Pharma but is known for execution in its chosen therapeutic areas. Read the latest domestic prescription data from industry sources for competitive context.
Is Divi's Labs affected by global drug pricing pressure?
Divi's Labs primarily operates in the API and custom synthesis segment, where pricing is negotiated directly with innovator and generic clients rather than through retail pharmacy channels. The pricing cycle in APIs depends on supply-demand dynamics for specific molecules rather than the generics price erosion seen in finished dosage forms.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Sun Pharma vs Cipla
Specialty-led US scale versus a balanced India and respiratory franchise
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise
Compare
HDFC Bank vs Kotak Bank
Post-merger liability scale versus a focused, capital-efficient compounder
Compare
Axis Bank vs ICICI Bank
A large-franchise turnaround versus best-in-class return and earnings quality
Compare
TCS vs Wipro
Margin and scale leadership versus a leaner, restructuring-led recovery
Compare
Infosys vs HCLTech
Guidance-led pure-services read versus a differentiated products-and-engineering mix
Compare
Sun Pharma vs Dr Reddy's
Specialty-led US scale versus a generics-and-CDMO-led global diversification
Compare
Nestle India vs Britannia
Focused multi-category brand power versus a biscuits-led margin compounder
Compare
ITC vs HUL
Conglomerate cash-and-value versus the broadest mass-market FMCG compounder
Compare
UltraTech Cement vs Grasim
The cement industry leader versus an Aditya Birla conglomerate with a cement holding and new businesses
Compare
SBI Life vs HDFC Life
Bancassurance scale through SBI versus a diversified product mix and balanced distribution
Compare
L&T vs Siemens India
A diversified domestic engineering conglomerate versus a focused industrial-technology franchise
Compare
Bajaj Auto vs Eicher Motors
Export-led volume scale and EV push versus the premium Royal Enfield franchise
Compare
DMart vs Trent
Everyday-value grocery scale versus a fast-fashion and format-expansion story
Compare
Asian Paints vs Pidilite
Decorative paint leadership versus a monopoly in construction adhesives
Compare
DLF vs Lodha
The oldest premium residential-and-commercial franchise versus the fastest-growing pan-India developer
Compare
Tata Power vs Adani Green
A diversified integrated power company versus a pure-play utility-scale renewables developer
Compare
TVS Motor vs Hero MotoCorp
A premium-and-premium-EV challenger versus the mass-market volume king
Compare
Shree Cement vs Ambuja Cements
The highest-margin, most efficient pure-play cement operator versus Adani-backed capacity scale
Compare
Cipla vs Zydus Lifesciences
A global respiratory and chronic-therapy generics leader versus an India-first FMCG-pharma blend with a biosimilar optionality
Compare
Tech Mahindra vs LTIMindtree
A telecom-anchored restructuring story versus a high-quality engineering-and-digital merger compounder
Compare
Tata Consumer vs Varun Beverages
A multi-category Tata group FMCG build-out versus the fastest-growing PepsiCo bottler franchise in the world
Compare
Adani Power vs NTPC
A private-sector capacity-growth story versus the sovereign-backed power PSU with a renewable pivot
Compare
Cholamandalam vs Shriram Finance
A diversifying vehicle and home-finance NBFC versus the dominant used-commercial-vehicle lender
Compare
Hindalco vs Vedanta
A globally integrated aluminium-and-copper compounder versus a diversified natural-resources conglomerate
Compare
Mahindra vs Hyundai India
The SUV-led domestic compounder with a farm and EV platform versus the premium Korean franchise in the Indian market
Compare
PFC vs REC Ltd
Broader power financing platform versus a focused utility lender
Compare
Bank of Baroda vs Canara Bank
Diversified PSU franchise with international presence versus a sharper domestic recovery
Compare
Wipro vs HCLTech
Turnaround execution potential versus a steadier IT services and products blend
Compare
Godrej Consumer Products vs Dabur
Personal care and home care momentum versus defensive staples and wellness breadth
Compare
IndusInd Bank vs Kotak Bank
Higher-beta recovery potential versus quality-first private banking franchise
Compare
BPCL vs GAIL India
Downstream petroleum and refining leverage versus gas transmission and utility infrastructure
Compare
Tata Steel vs JSPL
Integrated steel scale and global diversification versus a focused domestic metals execution story
Compare
ABB India vs CG Power
Premium electrification and automation technology versus a capital goods recovery and execution story
Compare
Motherson vs Bosch India
Global multi-category auto-component scale versus premium engineering and technology in auto systems
Compare
Muthoot Finance vs Bajaj Finance
Specialist gold-backed lending versus a broad consumer and retail credit platform
Compare
Adani Energy Solutions vs Tata Power
Transmission and distribution network expansion versus an integrated utility and clean energy franchise